Overview

  • Product name
  • Description
    Rabbit polyclonal to FGF9 / GAF
  • Host species
    Rabbit
  • Tested applications
    Suitable for: IHC-P, WB, ELISA, Neutralisingmore details
  • Species reactivity
    Reacts with: Mouse, Rat
  • Immunogen

    Recombinant fragment corresponding to FGF9/ GAF.

  • Positive control
    • Recombinant rat FGF9 / GAF protein (ab9745) can be used as a positive control in WB.
  • General notes

    Previously labelled as FGF9.

Properties

Applications

Our Abpromise guarantee covers the use of ab9743 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent dilution. PubMed: 17192470
WB Use a concentration of 0.1 - 0.2 µg/ml.
ELISA Use a concentration of 0.5 µg/ml. Allows the detection of 0.2 - 0.4 ng/well of recombinant mFGF-9 (using 100µl/well antibody solution).
Neutralising Use a concentration of 0.025 - 0.06 µg/ml. for one-half maximal inhibition [ND50] of the biological activity of mFGF-9 (1.5 ng/ml).

Target

  • Function
    May have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors.
  • Tissue specificity
    Glial cells.
  • Involvement in disease
    Defects in FGF9 are the cause of multiple synostoses syndrome type 3 (SYNS3) [MIM:612961]. Multiple synostoses syndrome is an autosomal dominant condition characterized by progressive joint fusions of the fingers, wrists, ankles and cervical spine, characteristic facies and progressive conductive deafness.
  • Sequence similarities
    Belongs to the heparin-binding growth factors family.
  • Post-translational
    modifications
    Three molecular species were found (30 kDa, 29 kDa and 25 kDa), cleaved at Leu-4, Val-13 and Ser-34 respectively. The smaller ones might be products of proteolytic digestion. Furthermore, there may be a functional signal sequence in the 30 kDa species which is uncleavable in the secretion step.
    N-glycosylated.
  • Cellular localization
    Secreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • FGF 9 antibody
    • FGF-9 antibody
    • FGF9 antibody
    • FGF9_HUMAN antibody
    • Fibroblast growth factor 9 antibody
    • GAF (Glia-activafibroblast growth factor 9 (glia-activating factor) antibody
    • GAF antibody
    • Glia Activating Factor antibody
    • Glia-activating factor antibody
    • HBFG 9 antibody
    • HBFG9 antibody
    • HBGF-9 antibody
    • Heparin-binding growth factor 9 antibody
    • MGC119914 antibody
    • MGC119915 antibody
    • SYNS3 antibody
    see all

Images

  • All lanes : Anti-FGF9 / GAF antibody (ab9743) at 1/500 dilution

    Lane 1 : Recombinant FGF9 / GAF
    Lane 2 : Rat cerebral cortex membrane whole tissue lysate. at 15 µg

    Secondary
    All lanes : Mouse anti-rabbit IgG monoclonal at 1/1000 dilution

    Developed using the ECL technique.

    Exposure time: 30 seconds


    Blocking Step: 1% Milk for 1 hour at 16°C
    Gel Running Conditons: 15% gel Reduced, denaturing
    Observed Bands: 23kDa recombinant FGF9 - 46kDa in cerebral cortex membrane fraction.

    See Abreview

  • ab9743 staining FGF9 / GAF in mouse lymph node tissue by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded tissue sections). The sections were fixed in paraformaldehye prior to blocking with 10% serum for 1 hour at 20°C. The primary antibody was diluted 1/100 and incubated with the sample for 12 hours at 4°C. An HRP-conjugated Goat anti-Rabbit polyclonal was used as the secondary antibody, diluted 1/200.

    See Abreview

References

This product has been referenced in:
  • Dong N  et al. MicroRNA-182 prevents vascular smooth muscle cell dedifferentiation via FGF9/PDGFRß signaling. Int J Mol Med 39:791-798 (2017). WB . Read more (PubMed: 28259995) »
  • Steffes G  et al. Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects. PLoS One 7:e51065 (2012). IHC . Read more (PubMed: 23226461) »
See all 4 Publications for this product

Customer reviews and Q&As

1-3 of 3 Abreviews or Q&A

Question
Answer

Thank you for confirming these details and for your cooperation. The details provided enable us to closely monitor the quality of our products.

I am sorry this product did not perform as stated on the datasheet and for the inconvenience this has caused. As requested, I have issued a free of charge replacement with the order number ***.

To check the status of the order please contact our Customer Service team and reference this number.

Please note that this free of charge replacement vial is also covered by our Abpromise guarantee. Should you still be experiencing difficulties, or if you have any further questions, please do not hesitate to let us know.

I wish you the best of luck with your research.

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample
Mouse Tissue sections (Lymph node)
Antigen retrieval step
None
Permeabilization
No
Specification
Lymph node
Blocking step
Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 20°C
Fixative
Paraformaldehyde

Abcam user community

Verified customer

Submitted Jun 01 2011

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Western blot
Sample
Rat Tissue lysate - other (brain)
Gel Running Conditions
Reduced Denaturing (gel 15%)
Loading amount
15 µg
Specification
brain
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 16°C

Abcam user community

Verified customer

Submitted Apr 21 2010

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up